Graves Disease Clinical Trial
Official title:
Thyroid-stimulating Immunoglobulins Level in Patients With Graves' Disease Undergoing Maintenance-dose of Antithyroid Drug and Its Relationship With Disease Relapse
The goal of this observational study is to determine the role of TSI, as well as clinical signs and thyroid function tests in predicting Graves' disease (GD) relapse after withdrawing anti thyroid drug (ATD). The main questions it aims to answer are: 1. To investigate the serum TSI concentration in patients with GD undergoing maintenance-dose ATD. 2. To determine an optimal cut-off of TSI level for predicting GD relapse. 3. To determine the role of TSI in predicting Graves' disease relapse after withdrawing ATD.
Retrospective follow-up study of patients with hyperthyroidism due to Graves' disease, treated at the endocrine outpatient clinic of Medic Medical Center, Ho Chi Minh City from January 2000 to April 2021. TSI was measured several times during the course of treatment when planning to stop medication (at the discretion of the attending physician). ATD withdrawal would be planned when patients achieved euthyroid status clinically with normal FT4 tests for at least 3 months with minimal dose of ATD. The decision was also based on TSI concentration, goiter's characteristics and parenchymal vascularity on Doppler ultrasound. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Completed |
NCT02973802 -
ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
|
Phase 1 | |
Completed |
NCT02491567 -
DNA Methylation and Autoimmune Thyroid Diseases
|
||
Terminated |
NCT01320813 -
Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy
|
N/A | |
Completed |
NCT00432146 -
Effect of Lugol's Solution in the Patients With Graves' Disease
|
N/A | |
Recruiting |
NCT06081439 -
Validating Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Not yet recruiting |
NCT06327828 -
Methimazole in Graves' Disease - Comparing the Computer-aided Treatment DigiThy Versus Usual Care
|
N/A | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04135573 -
The Relationship Between NK Cell and Graves' Disease
|
||
Recruiting |
NCT06134219 -
Course for Brain Fatigue After Graves' Disease Controlled Study
|
N/A | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Completed |
NCT03009357 -
Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis
|
||
Recruiting |
NCT05510609 -
Three-dimensional Ultrasonography Thyroid Volume Measurement.
|
N/A | |
Not yet recruiting |
NCT06426758 -
Graves' Disease Induced by Epstein-Barr Virus Lytic Reactivation
|
||
Recruiting |
NCT05907668 -
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
|
Phase 2 | |
Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
Recruiting |
NCT03303053 -
Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
|
Phase 3 | |
Recruiting |
NCT05461820 -
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
|
Phase 4 |